Acrivon Therapeutics, Inc. (ACRV)
(Delayed Data from NSDQ)
$7.33 USD
-0.23 (-3.04%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $7.33 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACRV 7.33 -0.23(-3.04%)
Will ACRV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ACRV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACRV
Verastem (VSTM) Begins Dosing in Solid Tumors Study in China
AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU
ACRV: What are Zacks experts saying now?
Zacks Private Portfolio Services
SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
Other News for ACRV
Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?
Optimistic Buy Rating for Acrivon Therapeutics Based on Promising ACR-2316 Prospects and Innovative AP3 Platform
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
Acrivon Therapeutics: A Buy Rating on Strong Clinical and Financial Prospects
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024